Eli Lilley & Pfizer are coat tailing the hard work done by Abbvie in the bioDMARD area Abbvie's new clinical indication for existing drug Humira is idiopathic arthritis (even children) not responsive to traditional Arthritis therapies Suspect EL & PF are trying to play catch up in this space. Currently PBS listing in AUS is Authority only S100 just not specified as RA indication....yet! . In the US they're already using for Humira for RA. This drug is not for everyone with lots of warnings & side effects & that's MSB point of difference. The trials all show it does no harm. That's unheard of for any drug in trial bringing these results. Time always tells.
Eli Lilley & Pfizer are coat tailing the hard work done by...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |